Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

Dec 27, 2022

GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2022 / RELIEF+THERAPEUTICS+Holding+SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), announced today that it has filed Amendment No. 2 to its Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed offering of its ordinary shares in the form of American Depositary Shares (ADSs). The preliminary prospectus provides for the possible sale of 833,333,200 ordinary shares in the form of ADSs (4,166,666 ADSs) in the United States and warrants to purchase 625,000,000 ordinary shares in the form ADSs (3,125,000 ADSs). In addition, the preliminary prospectus sets forth that Relief will grant the underwriters an option to purchase up to an additional 125,000,000 ordinary shares in the form of ADSs (625,000 ADSs) and additional warrants to purchase up to 93,750,000 additional shares in the form of ADSs (468,750 ADSs). The number of ADSs to be offered and the price range remain subject to change, and there can be no assurance that the offering contemplated by the registration statement will be completed. Relief will report the final terms of the contemplated offering once fixed in a future amendment to its registration statement. The offering, if made, will only be made by means of an effective prospectus. Further information is available in the Amendment No. 2 here .

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.